alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                             579
<SECURITIES>                                         0
<RECEIVABLES>                                      898
<ALLOWANCES>                                       207
<INVENTORY>                                     14,806
<CURRENT-ASSETS>                                18,354
<PP&E>                                          63,930
<DEPRECIATION>                                (20,305)
<TOTAL-ASSETS>                                 104,134
<CURRENT-LIABILITIES>                            8,969
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            65
<OTHER-SE>                                      29,089
<TOTAL-LIABILITY-AND-EQUITY>                   104,134
<SALES>                                        113,528
<TOTAL-REVENUES>                               120,465
<CGS>                                           24,510
<TOTAL-COSTS>                                   88,101
<OTHER-EXPENSES>                                32,997
<LOSS-PROVISION>                                   207
<INTEREST-EXPENSE>                               6,866
<INCOME-PRETAX>                                (7,706)
<INCOME-TAX>                                     3,200
<INCOME-CONTINUING>                            (4,506)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (4,506)
<EPS-BASIC>                                     (0.70)
<EPS-DILUTED>                                   (0.70)


</TABLE>
# L_2006283DE.01006201.xml

| 14.10.2006 | DE | Amtsblatt der Europäischen Union | L 283/62 |
| --- | --- | --- | --- |

14.10.2006

DE

Amtsblatt der Europäischen Union

L 283/62

---

Berichtigung der Verordnung (EG) Nr. 253/2006 der Kommission vom 14. Februar 2006 zur Änderung der Verordnung (EG) Nr. 999/2001 des Europäischen Parlaments und des Rates über Schnelltests und Maßnahmen zur Tilgung von TSE bei Schafen und Ziegen

(
  Amtsblatt der Europäischen Union L 44 vom 15. Februar 2006
  )

Amtsblatt der Europäischen Union L 44 vom 15. Februar 2006

Seite 11, Anhang, Nummer 2 Punkt 4, zweiter Absatz:

anstatt:

„Im Hinblick auf die Durchführung der Schnelltests ... zur TSE-Überwachung bei Rindern folgende Verfahren angewandt:“,

muss es heißen:

„Im Hinblick auf die Durchführung der Schnelltests ... zur TSE-Überwachung bei Schafen und Ziegen folgende Verfahren angewandt:“.

Seite 11, Anhang, Nummer 2 Punkt 4, zweiter Absatz, vierter Gedankenstrich:

anstatt:

„Chemilumineszenz-ELISA-Test mit Extraktionsverfahren ... chemilumineszenten Reagens (Enfer-Test)“,

muss es heißen:

„Chemilumineszenz-ELISA-Test mit Extraktionsverfahren ... chemilumineszenten Reagens (Enfer TSE Kit version 2.0)“.

---
<PAGE>   1
                                                                      EXHIBIT 23

                        [COOPERS & LYBRAND LETTERHEAD]


                      CONSENT OF INDEPENDENT ACCOUNTANTS


We consent to the incorporation by reference in the registration statement of
Meadowbrook Insurance Group, Inc. on Form S-3 (File No. 333-24083) of our
report dated March 10, 1997, on our audits of the consolidated financial
statements and financial statement schedule of Meadowbrook Insurance Group,
Inc. as of December 31, 1996 and 1995, and for the years ended December 31,
1996, 1995, and 1994, which report is incorporated by reference in this Annual
Report on Form 10-K

Coopers & Lybrand LLP


Detroit, Michigan
March 27, 1997
US ONCOLOGY HOLDINGS, INC.



Exhibit 32.2



CERTIFICATION PURSUANT TO

18
U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of US Oncology Holdings, Inc. (the Company) on Form 10-Q for the period ended September 30, 2005 as filed with the Securities and Exchange Commission on the date hereof (the
Report), I, Bruce D. Broussard, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
result of operations of the Company.



|                                                     
|-----------------------------------------------------
|/s/ Bruce D. Broussard                               
|Bruce D. Broussard                                   
|Chief Financial Officer of US Oncology Holdings, Inc.
|                                                     
|November 14, 2005                                    



-45-
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Mental Health Special Emphasis Panel; Global Mental Health Hubs.                    

*Date:*                         April 16, 2012.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Melrose Hotel, 2430 Pennsylvania Ave. NW., Washington, DC 20037.                    

*Contact Person:*                         Marina Broitman, Ph.D, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9608, Bethesda, MD 20892-9608, 301-402-8152,                         *mbroitma@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: March 1, 2012.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012-5705 Filed 3-7-12; 8:45 am]

BILLING CODE 4140-01-P
**Exhibit 31.2****CERTIFICATION**I, Susan J. Allread, certify that: 1. I have reviewed this Quarterly Report on Form 10-QSB of Greenville FederalFinancial Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made,in light of the circumstances under which such statements were made, not misleadingwith respect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the small business issueras of, and for, the periods presented in this report;  4. The small business issuer’s other certifying officer(s) and I are responsiblefor establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the small business issuer,including its consolidated subsidiaries, is made known to us by others withinthose entities, particularly during the period in which this report is beingprepared;(b) Evaluated the effectiveness of the small business issuer’s disclosurecontrols and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and(c) Disclosed in this report any change in the small business issuer’sinternal control over financial reporting that occurred during the smallbusiness issuer’s most recent fiscal quarter (the small business issuer’sfourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the small businessissuer’s internal control over financial reporting; and 5. The small business issuer’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financial reporting, tothe small business issuer’s auditors and the audit committee of the small businessissuer’s board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonablylikely to adversely affect the small business issuer’s ability to record,process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the small business issuer’s internalcontrol over financial reporting.        Date: November 10, 2006 /s/ Susan J. Allread   Susan J. Allread   Chief Financial Officer
II 

111TH CONGRESS 

1ST SESSION S. 2038 

To extend the duty suspension on Allyl isosulfocynate. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 29, 2009 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the duty suspension on Allyl isosulfocynate. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ALLYL ISOSULFOCYNATE. 

4 (a) IN GENERAL.—Heading 9902.01.41 of the Har5 monized Tariff Schedule of the United States (relating to 

6 Allyl isosulfocynate) is amended by striking ‘‘12/31/2009’’ 

7 and inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 

10 warehouse for consumption, on or after the 15th day after 

11 the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
#### Michael F. BEIRNE and Lake Otis Clinic, Inc., an Alaskan non-profit corporation, Appellants, v. Robert London SMITH, Commissioner of the Department of Health and Social Services; the Department of Health and Social Services of the State of Alaska; Humana Hospital Alaska, Inc., an Alaska corporation; and the Sisters of Providence in Washington, d/b/a Providence Hospital, Appellees.

No. S-810.

Supreme Court of Alaska.

Aug. 27, 1985.

Rehearing Denied Sept. 16, 1985.

Before RABINOWITZ, C.J., and BURKE, MATTHEWS and MOORE, JJ.

ORDER

IT IS HEREBY ORDERED:

The judgment of the superior court is AFFIRMED by an evenly divided court.1

COMPTON, J., not participating.

1

. Rabinowitz, Chief Justice, and Matthews, Justice, would remand to the commissioner, with instructions to file a decisional document explaining the basis of his decision.
EXHIBIT
32.1




AULTRA
GOLD INC.




CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,




AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report of Aultra Gold Inc. (the Company) on Form
10-Q for the period ended March 31, 2009 as filed with the Securities and
Exchange Commission on the date hereof (the Report), I, Rauno Perttu, President
and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:




(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and




(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.




A signed
original of this written statement required by Section 906 has been provided to
the Company  and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.




Date: May
      14, 2009
              By:
              /s/ 
      Rauno
      PerttuRauno
      PerttuPresident
      and Chief Executive
                Officer
#### 61 West 62nd Owners Corp., Respondent, v Harkness Apartment Owners Corp. et al., Appellants.

Order, Supreme Court, New York County (Irma Vidal Santaella, J.), entered May 25, 1990 ("Order-1”) which, *inter alia,*granted defendants a *Yellowstone*injunction conditioned on the posting of an undertaking in the amount of $500,000 and payment of "use and occupancy” *pendente lite;*and order of the same Court, entered November 2, 1990 ("Order-2”) which, *inter alia,*directed entry of a judgment in favor of plaintiff against defendant Barklease Corp. in the sum of $520,182.64, unanimously affirmed, with costs.

This case arises out of a dispute over leasehold obligations under a Master Lease entered into on December 17, 1985 for the commercial portion of premises located at 61 West 62nd Street in Manhattan. Plaintiff-landlord sought, *inter alia,*a declaration modifying and reforming certain obligations under the Master Lease, particularly with respect to maintenance of the building’s atrium, which it contends is defendant-tenant’s responsibility as commercial lessee. Defendants sought, and were granted a *Yellowstone*injunction to prevent termination of the Master Lease pending determination of defendants’ affirmative defenses and counterclaims, on condition that defendant-tenant post an undertaking in the amount of $500,000 and pay outstanding and prospective use and occupancy. Defendant did not post the undertaking, contending that it was twice the amount sought for past due rent, and moved to reargue and renew, and for partial summary judgment. Plaintiff cross-moved for entry of a money judgment for outstanding use and occupancy and vacatur of the *Yellowstone*injunction. The court denied the motion to reargue and renew in its entirety and granted plaintiff’s motion for a monetary judgment in its favor.

Initially, we observe that the Notice of Default was not improperly served, as the Master Lease does not prescribe any particular method of notification. Nor did the court err in granting judgment, for "use and occupancy” *(see, MMB Assocs. v Dayan,*169 AD2d 422), or in conditioning the issuance of the *Yellowstone*injunction upon future payment of "use and occupancy” *(Calvert v Le Tam Realty Corp.,*118 AD2d 426).

The court did not err in calculating the amount of the *373judgment, less an offsetting credit in the amount of a promissory note to defendants, pending proof at a later date of the full amounts owed. The amount of the undertaking was not excessive, but was rationally related to the quantum of damages which plaintiff would sustain in the event that defendant is later determined not to have been entitled to the injunction (CPLR 6212 [b]; *Margolies v Encounter, Inc.,*42 NY2d 475; *Weitzen v 130 E. 65th St. Sponsor Corp.,*86 AD2d 511). The court also properly refused to grant summary judgment dismissing the various causes of action, finding the existence of issues of fact. Concur—Sullivan, J. P., Carro, Rosenberger, Ross and Smith, JJ.
Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Chelsea Therapeutics International, Ltd. (the Company) for the period
ended June 30, 2010 as filed with the Securities and Exchange Commission on or about the date hereof (the Report), I, J. Nick Riehle, Vice President, Administration and Chief Financial Officer, hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the
periods presented in the Report.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



/s/ J. Nick RiehleJ. Nick RiehleVice President, Administration and Chief Financial OfficerJuly 27, 2010
EXHIBIT 32.1
  CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF
 BAYING ECOLOGICAL HOLDING GROUP INC.
 FORM 10-Q FOR THE THREE MONTH PERIOD ENDED DECEMBER 31, 2009
 PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
 PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  I, Parsh Patel, am the Chief Executive Officer of Baying Ecological Holding Group Inc., a Nevada corporation (the "Company"). I am delivering this certificate in connection with the Quarterly Report on Form 10-Q of the Company for the three month period ended December 31, 2009 and filed with the Securities and Exchange Commission ("Quarterly Report").
  Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Quarterly Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


July 31, 2014
By:
/s/ Parsh PatelParsh PatelPresident, Chief Executive Officer, Chief Financial Officer and Treasurer
### NUMBER S 13 - 1 3 - 00 364 - CR & 13 - 1 3 - 00 365 - CR & 13 - 13 - 366 - CR COURT OF APPEALS THIRTEENTH DISTRICT OF TEXAS CORPUS CHRISTI - EDINBURG

DONNIE LEE WARD , Appellant , v. THE STATE OF TEXAS , Appellee.

On appeal from the Criminal District Court No. 7

of Dallas County , Texas.


## MEMORANDUM OPINION Before Chief Justice Valdez and Justices Garza and Perkes

Memorandum Opinion Per Curia m Appellant, Donnie Lee Ward , attempts to appeal a conviction for obstructing g overnment operations arising from cause number F
- 1142518
- Y , docketed in our Court
as cause number 13
- 1 3
- 00 364
- CR ; a conviction for tampering with physical evidence arising from trial court cause number F
- 1142519
- Y , docketed in our Court as cause number 13
- 1 3
- 00 365
- CR ; and a conviction for possession of a controlled substance arising from trial court cause number F
- 1240754
- Y , docketed in our Court as cause2

number 13
- 13
- 00366
- CR. 1 In each of these cases, t he trial court has certified this “ is a plea
- bargain case, and the defendant has NO rig ht of appeal .” See T EX
. R. A PP
. P

. 25.2(a)(2). On July 22, 2013 , this Court notified appellant ’ s counsel of the trial court ’ s certification s and ordered counsel to: (1) review the record s ; (2) determine whether appellant has a right to appeal in either cause ; and (3) forward to this Court, by letter, counsel ’ s findings as to whether appellant has a right to appeal, or, alternatively, advise this Court as to the existence of any amended certification s
. On August 12, 2013 , counsel filed a letter brief with this Court for each of these
causes . Counsel ’ s response does not establish: (1) that the certification s currently on file with this Court are incorrect, or (2) that appellant otherwise has a right to appeal in either cause

. The Texas Rules of Appellate Procedure provide that an appeal must be dismissed if the trial court ’ s certification does not show that the defendant has the right of appeal. T EX
. R. A PP
. P. 25.2(d); see T EX
. R. A PP
. P . 37.1, 44.3, 44.4. Accordingly, th ese appeal s are DIS MISSED. Any pending motions are denied as moot. PER CURIAM

Do not publish. T EX
. R. A PP
. P . 47.2(b). D elivered and filed the 5th day of September , 201 3

.

1 Th ese case s are before the Court on transfer from the Fifth Court of Appeals in Dallas pursuant to a docket equalization order issued by the Supreme Court of Texas. See T EX . G OV ' T C ODE A NN . § 73.001 (West 2005).
EXHIBIT 32.1

CERTIFICATION OF
CHIEF EXECUTIVE OFFICER OF
TORO VENTURES INC.
FORM 10-Q FOR THE SIX MONTH PERIOD ENDED DECEMBER 31, 2010
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph Arcaro, am the Chief Executive
Officer of Toro Ventures Inc., a Nevada corporation (the "Company"). I am delivering this certificate in connection with
the Quarterly Report on Form 10-Q of the Company for the six month period ended December 31, 2010 and filed with the Securities
and Exchange Commission ("Quarterly Report").

Pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Quarterly
Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the
information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.



|Date: June 17, 2013                                                                     
|----------------------------------------------------------------------------------------
|By: /s/ Joseph Arcaro
        Joseph Arcaro
        Chief Executive Officer and Director